July 19, 2022 at 8:39 am

Virios’ Promising Fibromyalgia Treatment Candidate Expects September 2022 Phase 2b Results

With the aim of improving the standard of care for the 10 million Americans living with fibromyalgia (“FM”), Virios Therapeutics (Nasdaq: VIRI) anticipates Phase 2b results for its lead treatment candidate, oral IMC-1, in September. FM is a debilitating, chronic disorder characterized by widespread pain and severe fatigue, increased levels of depression, anxiety and trouble… [Read More]
July 15, 2022 at 9:10 pm

Cannabis Stocks are Soaring, After Senate Democrats Report

Cannabis stocks have had a hot week after a new report has revealed that Senate Democrats are planning to introduce a bill for federal decriminalization. Sources told Bloomberg that Majority Leader Chuck Schumer worked with Senators Cory Booker and Ron Wyden on the bill. The bill is called the Cannabis Administration and Opportunity act, and… [Read More]
July 15, 2022 at 3:32 pm

ProMIS Neurosciences Soars on First Nasdaq Trading Day

Newly uplisted biotech, ProMIS Neurosciences (Nasdaq: PMN)(TSX: PMN), soared on its first day of trading on Nasdaq, on Friday 8 July, closing up 44%. ProMIS is focused on developing antibody therapeutics for neurodegenerative diseases including Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease and multisystem atrophy (MSA). Neurodegenerative diseases are ultimately fatal and have no… [Read More]
July 14, 2022 at 9:29 pm

Canoo (GOEV) Jumps Another 29% From Potential Deal With the U.S. Army

Canoo (GOEV) is having a hot week. After soaring 53% on its deal with Walmart, the stock is jumping once again after the Company announced the the U.S. Army will be taking Canoo vans for analysis and demonstration. The Company has declined to comment on how many vehicles the Army are analyzing. “As an American… [Read More]
July 13, 2022 at 9:33 pm

Atara Biotherapeutics (ATRA) Drops 55% on Inconclusive Phase 2 Data

Atara Biotherapeutics (ATRA) plunged today on news that an interim analysis deemed its Phase 2 data for progress multiple sclerosis (MS) to be inconclusive. The Company stated that they believe “the six-month interim endpoint may be an inaccurate measure of the potential of this intervention in this condition,” and hope for more positive data in… [Read More]
July 06, 2022 at 11:22 pm

ThermoGenesis Holdings (THMO) Soars 31%

ThermoGenesis Holdings (THMO) shot up 31% for the day, despite not releasing any news. ThermoGenesis works in the gene therapy field and develops and commercializes automated cell processing technologies. THMO is currently a penny stock, sitting at $0.30 and a market cap slightly below $4M. THMO is also housed in the PRISM MedDiagnostics Index, which… [Read More]
July 06, 2022 at 1:28 pm

Quoin (NASDAQ:QNRX) Shares on the Move as Company Announces First Clinical Site Open to Evaluate Netherton Syndrome Treatment

In a significant step forward for rare disease treatment, Quoin Pharmaceuticals announced the opening of the first clinical site for its Netherton Syndrome study. The specialty pharma and biotech focused on rare and orphan diseases is well-positioned to potentially deliver the first FDA-approved treatment for the syndrome, a rare and devastating genetic disease with no… [Read More]
July 05, 2022 at 11:50 pm

Bitfarms (BITF) Shoots Up 17% in Big Day for Web 3.0 Index

Bitfarms (BITF) shot up 17% for the day, following a couple of highlights for the company. Recently, Bitfarms released their recap for their first Analyst & Investor Day, where they shared information about the company, how it works, and the team and where they see themselves going forward. Bitfarms presented itself as a “a low-cost… [Read More]
July 01, 2022 at 8:14 am

Oxford BioDynamics: A Winning Trifecta of Technology, Story and Strong Management

Biotechnology company, Oxford BioDynamics (AIM:OBD), is poised for successful commercialization of its precision medicine tests for oncology. Any seasoned investor will tell you that investing in biotechnology companies comes with an exhilarating balance of risk and reward. If a company is successful in getting its products to market, there is potential for significant investment gains…. [Read More]
June 30, 2022 at 12:43 am

SunPower (SPWR) Slides 11% on Weak Solar Outlook

SunPower (SPWR) fell around 11% today as the stock was initiated at Underweight by a Wells Fargo analyst. The reason behind the weak outlook is unsupported U.S. solar policies and a slowing housing market. “SunPower’s business is mostly direct sales, which we view as more sensitive to the economic environment given the large upfront cost… [Read More]
June 29, 2022 at 2:10 pm

The Ascension of Asensus in Performance-Guided Surgery

Key commercial and regulatory milestones expected during the second half of 2022 In a recent interview, Shameze Rampertab, CFO of Asensus Surgical (NYSE American: ASXC), shared more of the Performance-Guided Surgery™ company’s 2022 plans and progress. Asensus developed and commercialized a robotic surgical system—the Senhance® Surgical System—to elevate the work of surgeons and provide advanced… [Read More]